Business Wire

MORI-BUILDING

24.5.2021 04:02:10 CEST | Business Wire | Press release

Share
Toranomon-Azabudai Project and Toranomon Hills Area Project in Tokyo Precertified under LEED ND and WELL

Mori Building Co., Ltd., Japan’s leading urban landscape developer, announced today that major redevelopments the company is undertaking in Tokyo have been precertified under the prestigious LEED (Leadership in Energy and Environmental Design) and WELL (WELL Building Standard) rating systems that respectively certify environmentally friendly and efficient green buildings and people’s wellbeing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210523005028/en/

The Toranomon-Azabudai Project and Toranomon Hills Area Project both received top Platinum-level LEED ND (Neighborhood Development, v.4) precertifications. The Toranomon-Azabudai and Toranomon Hills Area projects are respectively the first and second projects in Tokyo to be precertified Platinum in the ND category. LEED is the most widely used green-building rating system that evaluates and certifies buildings and cities worldwide for environmental performance in terms of water and energy efficiency, indoor environments and sustainable materials. LEED is managed by the U.S. Green Building Council (USGBC).

The A District of the Toranomon-Azabudai Project and the A-1 District of Toranomon Hills Station Tower (tentative name) received WELL (Core,v.2 Pilot) precertifications; the former is the world’s largest precertified property and the latter is Japan’s second largest precertified property. WELL is the world’s first performance-based system for measuring, certifying and monitoring features of the built environment that impact human health and wellbeing through air, water, nourishment, light, fitness, comfort and mind. WELL is also managed by the USGBC. Once completed, both projects are expected to obtain WELL Platinum certifications.

Mahesh Ramanujam, president and CEO of USGBC and also Green Business Certification Inc., which provides third-party credentialing and verification under the LEED, WELL and GRESB systems, said:
“Mori Building’s sustainability efforts and its LEED Platinum achievement are fine examples of how organizations can transform their communities by lowering carbon emissions, creating healthier environments and work towards a zero-carbon future. Through awarding advanced examples such as Mori building, we aspire to demonstrate how better buildings, better communities and better cities can help raise the living standard for all.”

Mori Building, based on its philosophy of “Create cities, nurture cities,” is committed to realizing a sustainable global society through the harmonious coexistence of cities and nature, low-carbon cities and truly enhanced health.

LEED ND Platinum Precertifications

The Toranomon-Azabudai Project was highly evaluated as a complex with diverse urban functions, a walkable urban center built with a central square, and also for its renewable-energy power supply. Toranomon Hills Station Tower was favorably assessed for its integration of public transportation, including the new subway station, and high-level energy efficiency.

In both projects, Mori Building’s emphasis on urban development in partnership with local landowners earned high marks in the ND category. Toranomon-Azabudai Project became Tokyo’s first project to earn a Platinum level in the ND category and Toranomon Hills Area Project quickly followed as the second such project. It is globally rare for complexes in urban business areas to receive Platinum-level precertification.

WELL Platinum Precertifications

The Toranomon-Azabudai Project’s A District and Toranomon Hills Station Tower (tentative name)’s A-1 District were highly evaluated as advanced urban redevelopments following the concept of each project, offering central squares with substantial greenery, indoor environments with excellent air quality through use of air conditioners equipped with high-performance filters, cafes serving healthful meals and layouts featuring central squares and elevated decks to promote exercise. Once completed, both projects are expected to obtain Platinum certifications.

The A District of the Toranomon-Azabudai Project is the world’s largest precertified property and the A-1 District of Toranomon Hills Station Tower (tentative name) is Japan’s second largest precertified property.

Reference: Toranomon-Azabudai Project
https://www.mori.co.jp/en/img/article/210524_2.pdf

About Toranomon-Azabudai Project
https://www.mori.co.jp/en/projects/toranomon_azabudai/  

Toranomon-Azabudai Project Image Movie
https://www.youtube.com/watch?v=5akVE7tWOto&feature=emb_logo  

Reference: Toranomon Hills Area project
https://www.mori.co.jp/en/img/article/210524_3.pdf

About Toranomon Hills Area project
https://www.mori.co.jp/en/projects/toranomonhills_area/  

Press releases:
https://www.mori.co.jp/en/img/article/190822.pdf
https://www.mori.co.jp/en/img/article/200610_1.pdf
https://www.mori.co.jp/en/img/article/210218_1.pdf  

About Mori Building

Mori Building is an innovative urban developer based in Tokyo. The company is committed to maximizing the magnetic power of cities by creating and nurturing safe, sustainable and cosmopolitan urban centers based on its unique Vertical Garden City concept of high-rise centers for business, education, leisure and residence. The concept is applied in the company’s many leading-edge projects, including ARK Hills, Roppongi Hills and Toranomon Hills in Tokyo and the Shanghai World Financial Center. Mori Building is also engaged in real estate leasing, project management and consultation. Please visit www.mori.co.jp/en

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye